Tilray, Inc. Series 2 Stock

$0.60

1.58% yesterday

Nasdaq, Jul 16, 10:17 pm CET

ISIN

US88688T1007

Symbol

TLRY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Tilray, Inc. Series 2 Stock price

$0.60

-7.08 92.15% 5Y

Nasdaq, Closing price Wed, Jul 16 2025

+0.01 1.58%

ISIN

US88688T1007

Symbol

TLRY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$615.9m

Enterprise Value

$690.8m

Net debt

$74.8m

Cash

$248.4m

Shares outstanding

973.8m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.7 | 0.7

EV/Sales

0.8 | 0.8

EV/FCF

negative

P/B

0.2

Financial Health

Equity Ratio

81.6%

Return on Equity

-7.1%

ROCE

-3.4%

ROIC

-3.4%

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$826.7m | $866.1m

EBITDA

$-19.9m | $58.4m

EBIT

$-106.8m | $-482.7m

Net Income

$-945.7m | $-983.3m

Free Cash Flow

$-87.4m

Growth (TTM | estimate)

Revenue

11.2% | 9.8%

EBITDA

-112.1% | 577.9%

EBIT

-239.6% | -397.8%

Net Income

-168.7% | -301.4%

Free Cash Flow

-74.9%

EPS

$-1.1

FCF per Share

$-0.1

Short interest

19.8%

Employees

Rev per Employee

$300.0k

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

Tilray, Inc. Series 2 Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Tilray, Inc. Series 2 forecast:

8x Buy

47%

9x Hold

53%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Tilray, Inc. Series 2 forecast:

Buy

47%

Hold

53%

Analyst Estimates with Stock Price Targets

Financial data from Tilray, Inc. Series 2

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Feb '25		+/- %
Revenue	827 827	11% 11% 100%
- Direct Costs	571 571	7% 7% 69%
Gross Profit	255 255	23% 23% 31%
- Selling and Administrative Expenses	274 274	353% 353% 33%
- Research and Development Expense	0.64 0.64	39% 39% 0%
EBITDA	-20 -20	112% 112% -2%
- Depreciation and Amortization	87 87	0% 0% 11%
EBIT (Operating Income) EBIT	-107 -107	240% 240% -13%
Net Profit	-946 -946	169% 169% -114%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tilray, Inc. Series 2 Stock News

Positive

Invezz

●

one day ago

Tilray Brands stock price is surging: time to buy or sell?

Tilray Brands stock price has triggered a short squeeze this month as it surged to a high of $0.6570, its highest point since April 1, and 90% from its lowest point this year. Its market capitalization has jumped to over $680 million.

Positive

The Motley Fool

●

one day ago

Up Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher?

The S&P 500 index has been hitting record highs and may be running out of room to rise a whole lot more. For investors, now may be an opportune time to pay attention to stocks which may be poised for greater gains and which haven't been doing particularly well.

Neutral

MarketBeat

●

2 days ago

Tilray Shares Blazing: What's Behind the 55% Rally This Month?

Tilray Brands Inc. NASDAQ: TLRY, once a leading light in the legal cannabis industry with shares trading as high as nearly $150, has seen its stock price almost entirely collapse in recent years. A multitude of factors may be to blame—the lack of federal legalization of recreational cannabis, regulatory inconsistencies, problems matching supply and demand, and more have all devastated the indus...

More Tilray, Inc. Series 2 News

Company Profile

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Head office	United States
CEO	Irwin Simon
Employees	2,650
Founded	2018
Website	www.tilray.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now